×
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
NASDAQ:RGNX

REGENXBIO Stock Forecast, Price & News

$24.38
-1.47 (-5.69%)
(As of 06/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$24.00
$26.24
50-Day Range
$19.35
$30.94
52-Week Range
$18.69
$46.46
Volume
675,777 shs
Average Volume
430,086 shs
Market Capitalization
$1.05 billion
P/E Ratio
11.34
Dividend Yield
N/A
Price Target
$48.78
30 days | 90 days | 365 days | Advanced Chart

Receive RGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter.

RGNX Stock Forecast (MarketRank)

Overall MarketRank

2.45 out of 5 stars

Medical Sector

172nd out of 1,433 stocks

Biological Products, Except Diagnostic Industry

30th out of 217 stocks

Analyst Opinion: 3.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -
REGENXBIO logo

About REGENXBIO (NASDAQ:RGNX)

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

RGNX Stock News Headlines

REGENXBIO (NASDAQ:RGNX) Trading Up 7%
Jennifer Zachary Joins REGENXBIO Board of Directors
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RGNX
Fax
N/A
Employees
372
Year Founded
N/A

Company Calendar

Last Earnings
5/04/2022
Today
6/29/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$48.78
High Stock Price Forecast
$82.00
Low Stock Price Forecast
$17.00
Forecasted Upside/Downside
+100.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.66666666666667
Research Coverage
9 Analysts

Profitability

Net Income
$127.84 million
Pretax Margin
24.20%

Debt

Sales & Book Value

Annual Sales
$470.35 million
Cash Flow
$3.08 per share
Book Value
$17.87 per share

Miscellaneous

Free Float
37,656,000
Market Cap
$1.05 billion
Optionable
Optionable
Beta
1.14














REGENXBIO Frequently Asked Questions

Should I buy or sell REGENXBIO stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" REGENXBIO stock.
View analyst ratings for REGENXBIO
or view top-rated stocks.

What is REGENXBIO's stock price forecast for 2022?

9 Wall Street analysts have issued 12 month price objectives for REGENXBIO's shares. Their RGNX stock forecasts range from $17.00 to $82.00. On average, they predict REGENXBIO's share price to reach $48.78 in the next year. This suggests a possible upside of 100.1% from the stock's current price.
View analysts' price targets for REGENXBIO
or view top-rated stocks among Wall Street analysts.

How has REGENXBIO's stock price performed in 2022?

REGENXBIO's stock was trading at $32.70 on January 1st, 2022. Since then, RGNX stock has decreased by 25.4% and is now trading at $24.38.
View the best growth stocks for 2022 here
.

When is REGENXBIO's next earnings date?

REGENXBIO is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for REGENXBIO
.

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) posted its quarterly earnings data on Wednesday, May, 4th. The biotechnology company reported ($1.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.29) by $0.33. The biotechnology company had revenue of $22.22 million for the quarter, compared to analysts' expectations of $28.13 million. REGENXBIO had a net margin of 21.38% and a trailing twelve-month return on equity of 17.92%.
View REGENXBIO's earnings history
.

Who are REGENXBIO's key executives?

REGENXBIO's management team includes the following people:
  • Mr. Kenneth T. Mills, Pres, CEO & Director (Age 47, Pay $1.72M)
  • Mr. Vittal K. Vasista, Exec. VP & Chief Financial Officer (Age 54, Pay $1.25M)
  • Mr. Curran M. Simpson M.S., Exec. VP and Chief Operations & Technology Officer (Age 60, Pay $924.95k)
  • Dr. Olivier Danos Ph.D., Exec. VP & Chief Scientific Officer (Age 64, Pay $842.08k)
  • Mr. Patrick J. Christmas II, J.D., Exec. VP & Chief Legal Officer (Age 51, Pay $1.11M)
  • Ms. Tricia Truehart, VP of Investor Relations & Corp. Communications
  • Mr. Andrew Yost, VP of Corp. Devel.
  • Ms. Shiva G. Fritsch, Chief People Officer
  • Dr. Laura A. Coruzzi J.D., Ph.D., Sr. VP of Intellectual Property (Age 69)
  • Mr. Ram Palanki, Sr. VP of Commercial Strategy & Operations

What is Ken Mills' approval rating as REGENXBIO's CEO?

3 employees have rated REGENXBIO CEO Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among REGENXBIO's employees.

What other stocks do shareholders of REGENXBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Square (SQ).

What is REGENXBIO's stock symbol?

REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."

Who are REGENXBIO's major shareholders?

REGENXBIO's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (15.28%), JPMorgan Chase & Co. (10.95%), Vanguard Group Inc. (9.44%), State Street Corp (6.15%), Dimensional Fund Advisors LP (1.81%) and First Manhattan Co. (1.61%). Company insiders that own REGENXBIO stock include Allan M Fox, Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Kenneth T Mills, Patrick J Christmas, Steve Pakola, Vittal Vasista and WR Stephens, Iii 2012 Trust.
View institutional ownership trends for REGENXBIO
.

Which major investors are selling REGENXBIO stock?

RGNX stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, JPMorgan Chase & Co., Goldman Sachs Group Inc., Gyon Technologies Capital Management LP, Citigroup Inc., Mirae Asset Global Investments Co. Ltd., Mirae Asset Global Investments Co. Ltd., and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have sold REGENXBIO company stock in the last two years include Allan M Fox, Curran Simpson, Kenneth T Mills, Patrick J Christmas, Steve Pakola, Vittal Vasista, and WR Stephens, Iii 2012 Trust.
View insider buying and selling activity for REGENXBIO
or view top insider-selling stocks.

Which major investors are buying REGENXBIO stock?

RGNX stock was purchased by a variety of institutional investors in the last quarter, including WS Management Lllp, State Street Corp, First Manhattan Co., Assenagon Asset Management S.A., American Century Companies Inc., Bank of America Corp DE, Jennison Associates LLC, and Dimensional Fund Advisors LP.
View insider buying and selling activity for REGENXBIO
or or view top insider-buying stocks.

How do I buy shares of REGENXBIO?

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is REGENXBIO's stock price today?

One share of RGNX stock can currently be purchased for approximately $24.38.

How much money does REGENXBIO make?

REGENXBIO (NASDAQ:RGNX) has a market capitalization of $1.05 billion and generates $470.35 million in revenue each year. The biotechnology company earns $127.84 million in net income (profit) each year or $2.15 on an earnings per share basis.

How many employees does REGENXBIO have?

REGENXBIO employs 372 workers across the globe.

How can I contact REGENXBIO?

REGENXBIO's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The official website for REGENXBIO is www.regenxbio.com. The biotechnology company can be reached via phone at (240) 552-8181 or via email at [email protected].

This page (NASDAQ:RGNX) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.